CUSIP: 54142F102
Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
12,580,316
-
Share change
-
-41,630
-
Total reported value
-
$124,293,000
-
Price per share
-
$9.88
-
Number of holders
-
32
-
Value change
-
-$515,277
-
Number of buys
-
13
-
Number of sells
-
14
Quarterly Holders Quick Answers
What is CUSIP 54142F102?
CUSIP 54142F102 identifies LOGC - LOGICBIO THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2019
-
Previous quarter:
Q4 2018
Recent filing periods for CUSIP 54142F102:
Institutional Holders of LOGICBIO THERAPEUTICS INC - COM (LOGC) as of Q1 2019
As of 31 Mar 2019,
LOGICBIO THERAPEUTICS INC - COM (LOGC) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,580,316 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Redmile Group, LLC, Board of Trustees of The Leland Stanford Junior University, FRANKLIN RESOURCES INC, SAMLYN CAPITAL, LLC, Lion Point Capital, LP, SPHERA FUNDS MANAGEMENT LTD., BlackRock Inc., and VANGUARD GROUP INC.
This page lists
32
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.